Home » Newsletters » BioWorld Science

BioWorld Science

March 26, 2018

View Archived Issues

Rheos Medicines launches with series A financing

Multivalent filovirus vaccines demonstrate immunogenicity and protection in nonhuman primates

European Commission approves Alofisel

EMA committee backs approval of Sandoz's biosimilar infliximab

New macrocyclic alpha-hydroxyphenylacetamide Mcl-1 inhibitor with in vivo efficacy against myeloma

Juluca receives positive opinion from EMA's CHMP

Cellivery investigates leptin-targeting antiobesity therapy

EMA committee issues negative opinion on Portola's betrixaban

First patient enrolled in phase III AEGIS-II study of CSL-112

VISTA protein identified as a biomarker and target in malignant pleural mesothelioma

Prevymis tablets and i.v. infusion approved in Japan

IMpower150 study of Tecentriq in NSCLC meets coprimary endpoint of overall survival

Phase IIb study of RPL-554 in COPD meets primary endpoint

Bayer Yakuhin receives Japanese approval of Sivextro

hVIVO reports initial results from phase IIb influenza challenge study of FLU-v

EMA recommends including new indication in Repatha label

European Commission grants orphan drug designation to ARGX-113 for myasthenia gravis

First-in-human data for KM-819 presented at ASCPT

Japanese authorities expand indication for Tafinlar and Mekinist combination therapy

IFM Therapeutics describes novel stimulator of interferon genes protein agonists

Shanghai Hansoh Biomedical, Jiangsu Hansoh Pharmaceutical Group patent CDK inhibitors

Amgen, Allergan receive positive opinion in E.U. for ABP-980

Novel thrombopoietin receptor agonists synthesized at Sichuan Kelun-Biotech Biopharmaceutical

Gachon University identifies novel AChE/NO production inhibitors

New indication, new formulation of Signifor LAR approved in Japan

Bristol-Myers Squibb discovers new Toll-like receptor 7, 8 and 9 antagonists

Lenvima approved in Japan for unresectable HCC

Peloton initiates phase II study of PT-2977 for VHL-associated renal cell carcinoma

Genentech develops anti-inflammatory nuclear receptor ROR-gamma inverse agonists

CHMP supports conditional marketing authorization for Clovis Oncology's Rubraca

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...